BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 19901109)

  • 1. Acute myeloid leukemia with myeloid sarcoma and eosinophilia: prolonged remission and molecular response to imatinib.
    Védy D; Muehlematter D; Rausch T; Stalder M; Jotterand M; Spertini O
    J Clin Oncol; 2010 Jan; 28(3):e33-5. PubMed ID: 19901109
    [No Abstract]   [Full Text] [Related]  

  • 2. Long-term remission in a patient with BCR/ABL-positive acute myeloid leukaemia on maintenance therapy with imatinib.
    Schalk E; Neum S; Kranz S; Scheinpflug K; Mohren M
    Leuk Res; 2009 Mar; 33(3):e6-7. PubMed ID: 18466968
    [No Abstract]   [Full Text] [Related]  

  • 3. Development of acute myeloid leukemia associated with Ph-negative clone with inv(3)(q21q26) during imatinib therapy for chronic myeloid leukemia.
    Dvorak P; Hruba M; Subrt I
    Leuk Res; 2009 Jun; 33(6):860-1. PubMed ID: 18977531
    [No Abstract]   [Full Text] [Related]  

  • 4. Philadelphia chromosome-positive acute myeloid leukemia (Ph + AML) treated with imatinib mesylate (IM): a report with IM plasma concentration and bcr-abl transcripts.
    Kondo T; Tasaka T; Sano F; Matsuda K; Kubo Y; Matsuhashi Y; Nakanishi H; Sadahira Y; Wada H; Sugihara T; Tohyama K
    Leuk Res; 2009 Sep; 33(9):e137-8. PubMed ID: 19371951
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acute myeloid leukemia developing during imatinib mesylate therapy for chronic myeloid leukemia in the absence of new cytogenetic abnormalities.
    Pawarode A; Sait SN; Nganga A; Coignet LJ; Barcos M; Baer MR
    Leuk Res; 2007 Nov; 31(11):1589-92. PubMed ID: 17391756
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Results of imatinib mesylate therapy in patients with refractory or recurrent acute myeloid leukemia, high-risk myelodysplastic syndrome, and myeloproliferative disorders.
    Cortes J; Giles F; O'Brien S; Thomas D; Albitar M; Rios MB; Talpaz M; Garcia-Manero G; Faderl S; Letvak L; Salvado A; Kantarjian H
    Cancer; 2003 Jun; 97(11):2760-6. PubMed ID: 12767088
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Imatinib mesylate for refractory acute myeloblastic leukemia harboring inv(16) and a C-KIT exon 8 mutation.
    Nanri T; Matsuno N; Kawakita T; Mitsuya H; Asou N
    Leukemia; 2005 Sep; 19(9):1673-5. PubMed ID: 16049512
    [No Abstract]   [Full Text] [Related]  

  • 8. Achieving a major molecular response at the time of a complete cytogenetic response (CCgR) predicts a better duration of CCgR in imatinib-treated chronic myeloid leukemia patients.
    Iacobucci I; Saglio G; Rosti G; Testoni N; Pane F; Amabile M; Poerio A; Soverini S; Bassi S; Cilloni D; Bassan R; Breccia M; Lauria F; Izzo B; Merante S; Frassoni F; Paolini S; Montefusco E; Baccarani M; Martinelli G;
    Clin Cancer Res; 2006 May; 12(10):3037-42. PubMed ID: 16707599
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Response and resistance in 300 patients with BCR-ABL-positive leukemias treated with imatinib in a single center: a 4.5-year follow-up.
    Lahaye T; Riehm B; Berger U; Paschka P; Müller MC; Kreil S; Merx K; Schwindel U; Schoch C; Hehlmann R; Hochhaus A
    Cancer; 2005 Apr; 103(8):1659-69. PubMed ID: 15747376
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term remission in BCR/ABL-positive AML-M6 patient treated with Imatinib Mesylate.
    Pompetti F; Spadano A; Sau A; Mennucci A; Russo R; Catinella V; Franchi PG; Calabrese G; Palka G; Fioritoni G; Iacone A
    Leuk Res; 2007 Apr; 31(4):563-7. PubMed ID: 16916543
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Efficacy of imatinib mesylate, a specific inhibitor of BCR/ABL tyrosine kinase, on chronic myeloid leukemia in blast phase].
    Zhang GC; Zheng D; Li QH; Li XH; Cai CC; Luo SK; Li J; Peng AH; Tong XZ; Tan EX; Hong WD
    Ai Zheng; 2004 Dec; 23(12):1696-9. PubMed ID: 15601563
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Complete response to imatinib mesylate treatment in a 12-month-old patient with chronic myeloid leukemia.
    Arancibia AM; Bendit I; Epelman S
    Pediatr Blood Cancer; 2008 May; 50(5):1078. PubMed ID: 18085674
    [No Abstract]   [Full Text] [Related]  

  • 13. Outcome of four patients with chronic myeloid leukemia after imatinib mesylate discontinuation.
    Merante S; Orlandi E; Bernasconi P; Calatroni S; Boni M; Lazzarino M
    Haematologica; 2005 Jul; 90(7):979-81. PubMed ID: 15996937
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Imatinib failed to eradicate chronic myeloid leukemia in a patient with minimal residual disease.
    Franceschino A; Tornaghi L; Piazza R; Pogliani E; Gambacorti Passerini C
    Haematologica; 2006 Jun; 91(6 Suppl):ECR14. PubMed ID: 16785120
    [No Abstract]   [Full Text] [Related]  

  • 15. C-kit-positive acute myelogenous leukemia effectively treated with imatinib: a case report and review of the literature.
    Ichikawa K; Aritaka N; Sekiguchi Y; Sugimoto KJ; Imai H; Komatsu N; Noguchi M
    Geriatr Gerontol Int; 2012 Oct; 12(4):762-4. PubMed ID: 22998385
    [No Abstract]   [Full Text] [Related]  

  • 16. Achievement of complete molecular responses in late chronic phase chronic myeloid leukaemia patients treated with pulsed imatinib while in minimal residual disease.
    Breccia M; Cannella L; Stefanizzi C; Santopietro M; De Cuia R; Diverio D; Alimena G
    Leuk Res; 2009 May; 33(5):645-8. PubMed ID: 19062090
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intraoral granulocytic sarcoma presenting as multiple maxillary and mandibular masses: a case report and literature review.
    Xie Z; Zhang F; Song E; Ge W; Zhu F; Hu J
    Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2007 Jun; 103(6):e44-8. PubMed ID: 17428693
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of imatinib mesylate on patients with Philadelphia chromosome-positive chronic myeloid leukemia with secondary chromosomal aberrations.
    Mohamed AN; Pemberton P; Zonder J; Schiffer CA
    Clin Cancer Res; 2003 Apr; 9(4):1333-7. PubMed ID: 12684401
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Induction chemotherapy and post-remission imatinib therapy for de Novo BCR-ABL-positive AML.
    Lazarevic V; Golovleva I; Nygren I; Wahlin A
    Am J Hematol; 2006 Jun; 81(6):470-1. PubMed ID: 16680752
    [No Abstract]   [Full Text] [Related]  

  • 20. Factors predicting molecular and cytogenetic response in chronic myeloid leukemia patients treated with imatinib.
    Roche-Lestienne C; Darré S; Laï JL; Facon T; Guilhot J; Preudhomme C
    Haematologica; 2005 Jan; 90(1):131-3. PubMed ID: 15642682
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.